Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

Investors in Bristol-Myers Squibb Company BMY need to pay close attention to the stock based on moves in the options market lately. That is because the July 18, 2025 $25 Call had some of the highest ...

Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The sto ...

Applied Systems announced last week that it would withdraw Epic from the UK after conducting a strategic review ...

The meaning of a bizarre symbol that can be found on buildings across the UK has been revealed. The symbol, an engraved arrow ...

Objectives To develop a consensual definition for the term ‘early axial spondyloarthritis—axSpA’—and ‘early peripheral spondyloarthritis—pSpA’. Methods The ASAS (Assessment of SpondyloArthritis ...

The State CET Cell, Maharashtra has announced the MAH CET 2025 results for BCA, BBA, BMS, and BBM programmes today, June 4, 2025. Candidates can access their results using their registered ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B for the German biotech.

Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to take on the dominance of MSD’s Keytruda (pembrolizumab) in solid tumour ...

BMS and BioNTech will jointly develop and commercialise the asset that targets both PD-L1 and VEGF-A. ... will mean BMS and BioNTech jointly share development and manufacturing costs on a 50:50 ...

BMS pledges $40B over five years to boost U.S. R&D, tech innovation, and pharmaceutical manufacturing under CEO Christopher Boerner. genprowebdirectory Sign in. Welcome! Log into your ...